Nanobody target GCC and uses in chimeric antigen receptor cell therapy
US11970548B2 · kind B2 · utility
0Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2022 |
| Grant date | Apr 30, 2024 |
| Priority date | — |
| Expiry date | Aug 23, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y406/01002
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.